Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting the expression or function of Piezo2, a receptor that senses ...

In idiopathic pulmonary fibrosis, higher risk of mortality and lung transplant is linked to small decreases in FVC% predicted and DLCO% predicted.

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly ...

The outcomes of patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Alongside the global adoption of antifibrotic therapies, there is currently relentless research for biomarkers and ...

Most of Dedra’s life was spent on the sidelines. She was diagnosed with cystic fibrosis – an inherited condition that causes mucus buildup in the lungs, and often leads to infections and damage to ...

A promising new treatment approach for idiopathic pulmonary fibrosis (IPF), a fatal and currently untreatable lung disease affecting over 3 million people globally, has been identified by Tulane ...

Munich, Germany – April 9, 2025-- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced its ...

Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterized by excessive fibrotic tissue ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million ...

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.

Get Instant Summarized Text (Gist) An FDA-approved cancer drug that blocks the CTLA4 protein enabled immune cells to clear senescent cells in a mouse model of idiopathic pulmonary fibrosis (IPF ...